Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1196 results
June 2018
-
Key ReleaseNovartis erhält positive CHMP-Stellungnahme für Kymriah® zur Behandlung zweier aggressiver Blutkrebsarten - ein wichtiger medizinischer Fortschritt für Patientinnen und Patienten in EuropaErste CHMP-Stellungnahme zu CAR-T-Zell-Therapie bei zwei verschiedenen Indikationen: DLBCL bei Erwachsenen und B-Zell-ALL bei Kindern Der Antrag auf Marktzulassung (MAA) basiert auf zwei…
-
Key ReleaseNovartis receives positive CHMP opinion for Kymriah® for treating two aggressive blood cancers, marking important medical advance for patients in EuropeFirst CHMP opinion for a CAR-T cell therapy in two distinct indications - DLBCL in adults and B-cell ALL in children Marketing Authorization Application (MAA) based on landmark global CAR-T…
-
Key ReleaseNovartis announces intention to seek shareholder approval for 100% spinoff of Alcon eye care devices business; initiates share buyback of up to USD 5 bnAlcon strategic review concludes that 100% spinoff in best interest of shareholders and consistent with the Novartis strategy of focusing as a medicines company Planned spinoff would create…
-
Key ReleaseNovartis gibt Absicht bekannt, die Genehmigung der Aktionäre für einen 100%igen Spin-off des Geschäfts mit ophthalmologischen Produkten von Alcon einzuholen und leitet gleichzeitig einen Aktienrück...Die strategische Überprüfung von Alcon ergibt, dass ein 100%iger Spin-off im besten Interesse der Aktionäre ist und im Einklang mit der Strategie von Novartis steht, sich als…
-
Key ReleaseNovartis annonce son intention de solliciter l'approbation des actionnaires pour la scission à 100% d'Alcon, sa division de produits ophtalmologiques, et initie un rachat d'actions à hauteur d'USD ...L'examen stratégique d'Alcon conclut qu'une scission à 100% serait dans l'intérêt des actionnaires et en ligne avec la stratégie de Novartis visant à se concentrer sur son activité pharmaceutique…
-
Media ReleaseNovartis presents new data demonstrating long-term efficacy, safety and tolerability of Aimovig® (erenumab) in patients with chronic and episodic migraineResults from a one-year study of efficacy and safety of Aimovig in chronic migraine and data from a three-year analysis assessing safety and tolerability of Aimovig in episodic migraine will be…
-
Media ReleaseNovartis International AG: Global study by Novartis and European Migraine and Headache Alliance reveals 60% of employed people with severe migraine miss, on average, a week of work per monthStudy reveals migraine causes significant disruption to daily life and work, which could be managed with better preventive treatments and workplace solutions Migraine is estimated to cost up to…
-
Media ReleaseNovartis Clear about Psoriasis survey data highlights challenges psoriasis patients face to achieve goal of clear skinSurvey data published in JEADV show that patients experienced four different treatments and three medical professionals on average before finding an efficacious therapy[1] New publication also…
-
Media ReleaseNovartis International AG: Alcon AcrySof® IQ PanOptix® trifocal intraocular lens shows superior visual performance in head-to-head trial post-cataract surgeryBetter visual outcomes for patients with the AcrySof IQ PanOptix intraocular lens at near and intermediate distance vision[1] Detailed findings presented at World Ophthalmology Congress 2018…
-
Media ReleaseNovartis JULIET trial of Kymriah demonstrates more than one-year durability of responses in adults with relapsed or refractory DLBCLOverall response rate was 52% and median duration of response was not reached at a median follow-up of 14 months, signifying responses were durable[1] Patients had a 65% chance of being…
-
Media ReleaseNovartis survey uncovers real-world impact of immune thrombocytopenia or ITP, a rare blood disease, on patients' quality of lifeFindings from more than 1,300 patients across 13 countries showed ITP had especially high impact for many patients on emotional well-being (36%) and ability to work (28%) About two-thirds of…
Pagination
- ‹ Previous page
- 1
- …
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- …
- 100
- › Next page